|Budget Amount *help
¥2,400,000 (Direct Cost: ¥2,400,000)
Fiscal Year 1987: ¥1,000,000 (Direct Cost: ¥1,000,000)
Fiscal Year 1986: ¥1,400,000 (Direct Cost: ¥1,400,000)
In order to know which anticancer drugs are more appropriate for high-dose chemotherapy (HC) with autologous bone marrow transplantation (BMT) in cancer therapy, we tested six drugs (ACNU, ADR, CY, MMC, VDS, VP-16) in sprague-Dawley (SD) rats. Two or three varying doses of each drug were given iv on day O, followed by syngeneic BM cells (5x10^7,iv) on day 2, and animals were observed for over 60 days. ADR caused a high rate of peripheral neuropathy rather than myelosuppression death, so ADR was considered to be inappropriate for HC-BMT. Among other five drugs, a beneficial effect of BMT was observed only with CY (300-400 mg/kg) and ACNU (40 mg/kg). In order to increase the beneficial effect of BMT, administration ways of CY and ACNU were designed, and better survival curves were obtained in the following administration groups; 1) (CY 200 mg/kg, days 0 & 1) BMT> (CY 400 mg/kg, day 0) BMT, (ACNU 20 mg/kg, day 0 & 1) BMT> (ACNU 40 mg/kg, day 0) BMT, 2) (CY 200 mg/kg ACNU 20 mg/kg, day 0) BMT>(CY 400 mg/kg or ACNU 40 mg/kg, day 0) BMT, 3) (CY 200 mg/kg, day 0) (acanau 20 mg/kg, day 1) BMT> (ACNU 20 mg/kg, day 0 ) (CY 200 mg/kg, day 1) BMT.
Among six anticancer drugs tested in this study, CY and ACNU were suggested to be more appropriate drugs for HC-BMT, but devices for reducing drug toxicity are considered to be necessary for increasing the beneficial effect of BMT.